Who
David Happel
President & CEO
Company insider
Files Form 4 as: President & CEO, Sagimet Biosciences; EVP, Commercial Dev & Strategy, Horizon Pharma; Chief Commercial Officer, Raptor Pharmaceutical.
In numbers
- Trades disclosed
- 31
- Buys
- 3
- Sells
- 3
- Bought
- $72K
- Sold
- $1.7M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 25 Nov 2014
- Last trade
- 20 Jul 2026
- Last filed
- 22 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Jul 2026filed 22 Jul 2026 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Sold | $497K64,051 at $7.76 | filing |
| 20 Jul 2026filed 22 Jul 2026 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Sold | $497K64,051 at $7.76 | filing |
| 28 May 2026filed 1 Jun 2026 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 28 May 2026filed 1 Jun 2026 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Code A | —128,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —256,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —256,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Code A | —128,000 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Sold | $65K12,101 at $5.36 | filing |
| 10 Feb 2026filed 12 Feb 2026 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Sold | $65K12,101 at $5.36 | filing |
| 21 Jul 2025filed 23 Jul 2025 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Sold | $598K65,478 at $9.13 | filing |
| 6 Feb 2025filed 7 Feb 2025 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —472,000 at $0.00 | filing |
| 6 Feb 2025filed 7 Feb 2025 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Code A | —116,000 at $0.00 | filing |
| 26 Mar 2024filed 28 Mar 2024 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Bought | $64K12,100 at $5.27 | filing |
| 7 Dec 2023filed 8 Dec 2023 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Bought | $6,5601,600 at $4.10 | filing |
| 17 Nov 2023filed 21 Nov 2023 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Code A | —624,910 at $0.00 | filing |
| 16 Nov 2023filed 20 Nov 2023 | SGMT Sagimet BiosciencesBiotechnology | SEC FORM 4 Bought | $1,387590 at $2.35 | filing |
| 18 Jul 2023filed 20 Jul 2023 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,011,826 at $0.00 | filing |
| 18 Jul 2023filed 20 Jul 2023 | SGMT Sagimet Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,011,826 at $0.00 | filing |
| 25 Oct 2017filed 26 Oct 2017 | Horizon Pharma | SEC FORM 4 Code M | —7,953 | filing |
News
No headline names them, or the companies they trade most, lately.